18F-FDG uptake in lung, breast, and colon cancers: Molecular biology correlates and disease characterization

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1820-1827

  Jadvar, Hossein ^a   Alavi, Abass ^b   Gambhir, Sanjiv S ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDG; Breast cancer; Colon cancer; Lung cancer; Molecular biology; Molecular imaging; Oncology; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; HEXOKINASE; DIAGNOSTIC AGENT;

BREAST CANCER; COLON CANCER; HUMAN; INTRADUCTAL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ANIMAL; BREAST TUMOR; COLON TUMOR; LUNG TUMOR; METABOLISM; PATHOLOGY; SCINTISCANNING;

ANIMALS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MOLECULAR BIOLOGY;

EID: 70350743151     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054098     Document Type: Review

References (101)

1. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661-681.
2. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693. (Pubitemid 37328919)
3. 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49(10):17N-21N, 37N.
4. Miles KA, Williams RE. Warburg revisited: imaging tumor blood flow and metabolism. Cancer Imaging. 2008;8:81-86.
5. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expression in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-1555. (Pubitemid 32953137)
6. Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317-322.
7. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.
8. Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol. 1994;21:827-834. (Pubitemid 24263576)
9. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49(6 suppl):24S-42S. (Pubitemid 351948035)
10. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008;49(6 suppl):43S-63S.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
12. Gambhir SS. Molecular imaging of cancer: from molecules to humans: introduction. J Nucl Med. 2008;49(suppl 2):1S-4S.
13. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008;8:56-61.
14. 18F-FDG distribution with regional expression of glucose transporters and hexokinase II in experimental tumor. J Nucl Med. 2005;46:675-682.
15. Strauss LG, Pan L, Koczan D, et al. Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging. 2007;26:804-812. (Pubitemid 46842915)
16. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res. 2002;35:9-26. (Pubitemid 34661867)
17. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci. 1999;56:285-292. (Pubitemid 30008823)
18. Macheda ML, Rogers S, Bets JD. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-662. (Pubitemid 40175840)
19. YounesM, Lechago LV, Somoano JR, et al. Immunohistochemical detection of glut3 in human tumors and normal tissues. Anticancer Res. 1997;17(4A):2747-2750.
20. Ito S, Fukusato T, Nemoto T, et al.Coexpression of glucose transporter 1 andmatrix metalloproteinase 2 in human cancers. J Natl Cancer Inst. 2002;94:1080-1091. (Pubitemid 34830728)
21. Rogers S, Macheda ML, Docherty SE, et al. Identification of a novel glucose transporter-like protein-glut-12. Am J Physiol Endocrinol Metab. 2002; 282:E733-E738. (Pubitemid 34654792)
22. Mathupala SP, Ko YH, Pederson PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25:4777-4786.
23. Wilson JE. Isoenzymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049-2057.
24. Pedersen PL. Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39:211-222.
25. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol. 2005;70:363-374.
26. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170-178.
27. Pastorino JG, Hoek JB. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem. 2003;10:1535-1551.
28. Golshani-Hebroni SG, Bessman SP. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr. 1997; 29:331-338.
29. 18F]2-fluoro-2- deoxyglucose as a function of the glucose-6-phosphatates enzyme system. J Biol Chem. 2000;275:18489-18494.
30. Jadvar H, Bading JR, Yu X, et al. Dynamic FDG PET kinetic analysis of inflammation and cancer: preliminary results. Paper presented at: Annual Meeting of the Academy of Molecular Imaging; October 24-28, 2001; Orlando, Florida.
31. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
32. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-1446.
33. Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging. 2008;53:9-16.
34. Pillot G, Siegel BA, Govindan R. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol. 2006;1:152-159. (Pubitemid 47164003)
35. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oven WJ. Predictive and prognostic value of FDG-PET in nonsmall cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664.
36. Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:269-288. (Pubitemid 38201560)
37. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39-45. (Pubitemid 34101186)
38. Kurata T, Oguri T, Isobe T, et al. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999;90:1238-1243.
39. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlated of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55:79-87. (Pubitemid 46038871)
40. Higashi K, Ueda Y, Sakurai A, et al. Correlation of GLUT-1 glucose transporter expression with. Eur J Nucl Med. 2000;27:1778-1785.
41. 18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med. 1999;40:339-346.
42. 18F]FDG uptake and PCNA, glut-1, and Hexokinase-II expression in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7:369-379.
43. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG PET imaging with GLUT-1 and GLUT-3 expression in early stage non-small cell lung cancer. Lung Cancer. 2001;33:99-107. (Pubitemid 32707892)
44. 18F-FDG PET results in lung cancer staging. J Nucl Med. 2004;45:999-1000.
45. Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556-565.
46. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation, grade, and tumor stage. Mod Pathol. 1998;11:437-443. (Pubitemid 28224445)
47. 18F]fluoro-D-glucose in human cancers heterotransplanted in nude mice: comparison between histology and glycolytic status. J Nucl Med. 1994;35: 97-103.
48. Yasuda S, Aril S, Mori A, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol. 2004;40:117-123. (Pubitemid 38064720)
49. Nguyen XC, So Y, Chung JH, et al. High correlations between primary tumors and locoregional metabolic lymph nodes in non-small cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-D-glucose uptake. Eur J Cancer. 2008;44:692-698.
50. 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606-1612.
51. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2008;61:54-60.
52. Khandani AH, Whitney KD, Keller SM, et al. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun. 2007;28:173-177.
53. Márián T, Szabó G, Goda K, et al. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging. 2003;30:1147-1154.
54. Higashi K, Ueda Y, Ikeda R, et al. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl Med Commun. 2004;25:19-27. (Pubitemid 38183947)
55. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, metabolism and angiogenesis in cancer: novel pathways and targets for anticancer chemotherapeutics. Chemotherapy. 2007;53:233-256. (Pubitemid 47074647)
56. Pedersen MW, Holm S, Lund EL, et al. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia. 2001;3:80-87. (Pubitemid 32201613)
57. 18F-FDG PET. J Nucl Med. 2006;47:1921-1926.
58. Nguyen XC, Lee WW, Chung JH, et al. FDG uptake, glucose transporter type 1, Ki-67 expressions in non-small cell lung cancer: correlations and prognostic values. Eur J Radiol. 2007;62:214-219.
59. 18Fdeoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1a and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392-1398.
60. 18F-FDG (fluorodeoxyglucose) uptake: a mouse study using positron emission tomography (PET). Radiat Oncol. 2006;1:3.
61. Sasaki M, Sugio K, Kuwabara Y, et al. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Ann Nucl Med. 2003;17:189-196. (Pubitemid 36834430)
62. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med. 1998;28:290-302.
63. Wu D, Gambhir SS. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. Clin Breast Cancer. 2003;4(suppl 1):S55-S63. (Pubitemid 36621617)
64. Rose C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun. 2002;23:613-618. (Pubitemid 34747999)
65. Eubank WB, Mankoff DA, Vesselle HJ, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics. 2002;22:5-17.
66. Grover-McKay M, Walsh SA, Seftor EA, et al. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res. 1998;4:115-120. (Pubitemid 28394627)
67. Brown RS, Goodman TM, Zasadny KR, et al. Expression of hexokinase II and glut-1 in untreated human breast cancer. Nucl Med Biol. 2002;29:443-453. (Pubitemid 34597116)
68. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between glut-1 expression and FDG uptake. J Nucl Med. 1996;37:1042-1047.
69. Brown RS, Wahl RL. Overexpression of glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993;72:2979-2985.
70. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
71. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323. (Pubitemid 44392212)
72. Shimoda W, Hayashi M, Murakami K, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260-268.
73. 18F]-fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429-1434.
74. 18F-FDG incorporation is enhanced by attenuation of p53 function in breast cancer cells in vitro. J Nucl Med. 2006;47:1525-1530.
75. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
76. Burgman P, O'Donoghue JA, Humm JL, et al. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001;42:170-175. (Pubitemid 32104796)
77. Buck AK, Schirrmeister H, Mattfeldt T, et al. Biological characterization of breast cancer by means of PET. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S80-S87. (Pubitemid 38833036)
78. Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98:267-274. (Pubitemid 44195596)
79. Basu S, Mavi A, Cermik T, et al. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18] fluoro-Dglucose- positron emission tomography predict tumor biology? Mol Imaging Biol. 2008;10:62-66.
80. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509.
81. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995-1000. (Pubitemid 351304582)
82. 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48:1266-1272.
83. 18F-FDG PET/CT)in primary breast cancer. Jpn J Clin Oncol. 2008;38:250-258.
84. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177-1189.
85. Tatlidil R, Jadvar H, Bading JR, et al. Incidental colonic [F-18]fluorodeoxyglucose uptake: correlation with colonoscopy and histopathology. Radiology. 2002;224:783-787. (Pubitemid 34919813)
86. Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol. 1999;26:577-583. (Pubitemid 29483284)
87. Liu FY, Chen JS, Changchien CR, et al. Utility of 2-fluoro-2-deoxy-D- glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum. 2005;48:1900-1912.
88. Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2006;33:779-784. (Pubitemid 43979685)
89. Kinner S, Antoch G, Bockisch A, Veit-Haibach P. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer. Abdom Imaging. 2007;32:606-612. (Pubitemid 47594245)
90. Nagata K, Ota Y, Okawa T, et al. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum. 2008;51:882-890.
91. Gambhir SS, Valk P, Shepherd J, et al. Cost effective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer [abstract]. J Nucl Med. 1997;38:90P.
92. 18F-2-fluoro-2-deoxy-D- glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006; 51:2198-2205.
93. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83:34-40. (Pubitemid 28299626)
94. Riedl CC, Akhurst T, Larson S, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771-775. (Pubitemid 47604978)
95. 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol Ther. 2007;6:1649-1653.
96. 18F-FDG in colorectal tumors. J Nucl Med. 2008;49:1238-1244.
97. Strauss LG, Klippel S, Pan L, et al. Assessment of quantitative FDG PET data in primary colorectal tumors: which parameters are important with respect to tumor detection? Eur J Nucl Med Mol Imaging. 2007;34:868-877.
98. Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001;60:162-169. (Pubitemid 32245335)
99. Sakashita M, Aovama N, Miami R, et al. GLUT1 expression in T1 and T2 stage colorectal carcinomas: its relationship to histopathological features. Eur J Cancer. 2001;37:204-209. (Pubitemid 32144697)
100. 18F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001;3:189-195.
101. Chung JH, Lee WW, Park SY, et al. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. Eur J Surg Oncol. 2006;32:989-995.